Valuation: Ondine Biomedical Inc.

Capitalization 38.73M 27.39M 25.92M 24.03M 21.49M 2.32B 42.87M 299M 111M 953M 103M 101M 4.11B P/E ratio 2024 *
-2.28x
P/E ratio 2025 * -2.28x
Enterprise value 24.83M 17.56M 16.62M 15.4M 13.78M 1.49B 27.48M 192M 70.86M 611M 65.97M 64.5M 2.63B EV / Sales 2024 *
9.37x
EV / Sales 2025 * 4.86x
Free-Float
53.11%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 month-11.43%
3 months+12.73%
6 months+6.90%
Current year-11.43%
More quotes
1 week
7.50
Extreme 7.5
8.00
1 month
7.50
Extreme 7.5
9.00
Current year
5.00
Extreme 5
11.40
1 year
5.00
Extreme 5
11.40
3 years
5.00
Extreme 5
60.00
5 years
5.00
Extreme 5
60.00
10 years
5.00
Extreme 5
60.00
More quotes
Director TitleAgeSince
Chief Executive Officer 62 2004-02-29
Director of Finance/CFO - 2024-03-27
President 64 2009-01-05
Manager TitleAgeSince
Director/Board Member 70 2009-03-31
Chairman 62 2009-03-29
Director/Board Member 64 2009-01-05
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
0.00%0.00%-22.50%-86.64%27.39M
+0.01%-2.67%+11.10%-12.70%201B
-0.15%-2.92%+5.61%-25.17%108B
-1.00%-0.85%-5.79%-12.12%63.61B
+0.82%+5.32%+23.05%+13.13%47.07B
-0.37%-3.24%+21.58%+103.66%47.05B
-1.19%+0.95%+29.93%+31.04%30.42B
-1.52%-0.35%-34.63%-44.33%30.36B
+1.35%-0.98%-5.48%-25.00%23.36B
-1.04%-3.63%-7.89%-15.88%21.5B
Average -0.31%-0.76%+1.50%-7.40% 57.16B
Weighted average by Cap. -0.23%-1.46%+7.21%-3.26%
See all sector performances

Financials

2024 *2025 *
Net sales 2.65M 1.87M 1.77M 1.64M 1.47M 159M 2.93M 20.46M 7.56M 65.22M 7.04M 6.88M 281M 6.2M 4.39M 4.15M 3.85M 3.44M 371M 6.86M 47.87M 17.7M 153M 16.47M 16.11M 657M
Net income -14.9M -10.54M -9.97M -9.24M -8.27M -893M -16.49M -115M -42.53M -367M -39.59M -38.71M -1.58B -30M -21.22M -20.08M -18.61M -16.65M -1.8B -33.21M -232M -85.62M -738M -79.71M -77.94M -3.18B
Net Debt -13.9M -9.83M -9.3M -8.62M -7.71M -833M -15.39M -107M -39.67M -342M -36.93M -36.11M -1.47B -8.6M -6.08M -5.76M -5.34M -4.77M -515M -9.52M -66.39M -24.55M -212M -22.85M -22.34M -912M
More financial data * Estimated data
Logo Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.
Employees
18
More about the company
Date Price Change Volume
24-12-06 7.750 p 0.00% 2,799
24-12-05 7.750 p 0.00% 160,228
24-12-04 7.750 p 0.00% 100,200
24-12-03 7.750 p 0.00% 1,221
24-12-02 7.750 p 0.00% 251,325

Delayed Quote London S.E., December 06, 2024 at 11:35 am EST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
surperformance-ratings-light-chart ONDINE-BIOMEDICAL-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0775GBP
Average target price
0.6000GBP
Spread / Average Target
+674.19%
Consensus

Annual profits - Rate of surprise